Pulse Biosciences, Inc. PLSE
Institutional shares held
4.72 Million
239K
calls
94.2K
puts
Total value of holdings
$58.5M
$2.96M
calls
$1.17M
puts
Market Cap
$460M
37,125,900
Shares Out.
Institutional ownership
12.72%
# of Institutions
67
We take great care to ensure that the data presented and summarized in this overview for Pulse Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PLSE
View all-
Black Rock Inc. New York, NY1.04MShares$12.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA847KShares$10.5 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC780KShares$9.65 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA391KShares$4.84 Million0.0% of portfolio
-
State Street Corp Boston, MA350KShares$4.33 Million0.0% of portfolio
-
Griffin Asset Management, Inc.300KShares$3.72 Million0.32% of portfolio
-
Northern Trust Corp Chicago, IL187KShares$2.32 Million0.0% of portfolio
-
Spotlight Asset Group, Inc. Oakbrook Terrace, IL72.1KShares$892,4740.46% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny61.4KShares$760,1320.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il54.1KShares$669,5350.0% of portfolio
Latest Institutional Activity in PLSE
Top Purchases
Top Sells
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Insider Transactions at PLSE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2024
|
Burke Thomas Barrett President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$80,000
$8.56 P/Share
|
|
Dec 12
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
17,999
+0.05%
|
$161,991
$9.15 P/Share
|
|
Dec 11
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
90,118
+0.24%
|
$811,062
$9.36 P/Share
|
|
Dec 08
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
116,656
+0.32%
|
$1,049,904
$9.54 P/Share
|
|
Dec 07
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
74,852
+0.2%
|
$673,668
$9.19 P/Share
|
|
Dec 06
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
82,813
+0.23%
|
$745,317
$9.06 P/Share
|
|
Dec 06
2023
|
Robert W Duggan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,933
+0.03%
|
$49,665
$5.95 P/Share
|
|
Dec 05
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Indirect |
66,021
+15.81%
|
$594,189
$9.34 P/Share
|
|
Dec 04
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Indirect |
27,000
+8.64%
|
$270,000
$10.38 P/Share
|
|
Dec 04
2023
|
Robert W Duggan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,347
+0.06%
|
$403,470
$10.66 P/Share
|
|
Dec 01
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Indirect |
45,600
+14.99%
|
$410,400
$9.07 P/Share
|
|
Nov 30
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Indirect |
152,944
+41.8%
|
$1,376,496
$9.06 P/Share
|
|
Nov 29
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Indirect |
60,000
+50.0%
|
$540,000
$9.21 P/Share
|
|
Nov 29
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
158,600
+0.43%
|
$1,427,400
$9.44 P/Share
|
|
Nov 29
2023
|
Robert W Duggan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,667
+0.0%
|
$8,335
$5.95 P/Share
|
|
Nov 28
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
124,397
+0.34%
|
$995,176
$8.98 P/Share
|
|
Nov 17
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
20,241
+0.02%
|
$121,446
$6.1 P/Share
|
|
Nov 16
2023
|
Kevin Patrick Danahy Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,393
+4.54%
|
$32,358
$6.51 P/Share
|
|
Nov 15
2023
|
Mitchell E. Levinson Chief Strategy Officer |
BUY
Open market or private purchase
|
Indirect |
13,539
+31.4%
|
$67,695
$5.93 P/Share
|
|
Nov 15
2023
|
Mitchell E. Levinson Chief Strategy Officer |
BUY
Open market or private purchase
|
Direct |
4,261
+2.8%
|
$21,305
$5.86 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.35M
Shares
From
6
Insiders
| Exercise of conversion of derivative security | 277K shares |
|---|---|
| Open market or private purchase | 1.07M shares |
Sell / Disposition
0
Shares
From
0
Insiders